{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:52:10Z","timestamp":1790779930123,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.neuropharm.2020.107997","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T01:58:31Z","timestamp":1581299911000},"page":"107997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets"],"prefix":"10.1016","volume":"167","author":[{"given":"Ria","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Hikima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Varney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Depoortere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Newman-Tancredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neuropharm.2020.107997_bib1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1743-6109.2011.02616.x","article-title":"Flibanserin and 8-OH-DPAT implicate serotonin in association between female marmoset monkey sexual behavior and changes in pair-bond quality","volume":"9","author":"Aubert","year":"2012","journal-title":"J. Sex. Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107997_bib2","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1124\/jpet.104.077669","volume":"312","author":"Bardin","year":"2005","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.107997_bib3","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.25366","article-title":"Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Movement disorders","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.neuropharm.2020.107997_bib4","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/jnr.21978","article-title":"Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats","volume":"87","author":"Bishop","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2020.107997_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.expneurol.2018.01.010","article-title":"Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT1A receptor biased agonists","volume":"302","author":"Brys","year":"2018","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107997_bib6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.neuropharm.2008.09.004","article-title":"Region-specific changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1\/2 phosphorylation in rat brain: a quantitative ELISA study","volume":"56","author":"Buritova","year":"2009","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.107997_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/00498258309052248","article-title":"Disposition and metabolism of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the rat","volume":"13","author":"Caccia","year":"1983","journal-title":"Xenobiotica"},{"issue":"Pt 2","key":"10.1016\/j.neuropharm.2020.107997_bib8","first-page":"319","article-title":"Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration","volume":"132","author":"Carlsson","year":"2009","journal-title":"Brain: J. Neurol."},{"issue":"30","key":"10.1016\/j.neuropharm.2020.107997_bib9","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1523\/JNEUROSCI.2079-07.2007","article-title":"Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson\u2019s disease","volume":"27","author":"Carlsson","year":"2007","journal-title":"J. Neurosci.\u202f: the official journal of the Society for Neuroscience"},{"issue":"pt 7","key":"10.1016\/j.neuropharm.2020.107997_bib10","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain: J. Neurol."},{"key":"10.1016\/j.neuropharm.2020.107997_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0079-6123(08)00922-9","article-title":"Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias","volume":"172","author":"Carta","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.107997_bib12","article-title":"Dyskinesia matters","author":"Cenci","year":"2019","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.107997_bib13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00259-019-04473-7","article-title":"18F-F13640 PET imaging of functional receptors in humans","volume":"47","author":"Colom","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.neuropharm.2020.107997_bib14","first-page":"40","article-title":"5-HT1A receptor activation: new molecular and neuroadaptive mechanisms of pain relief","volume":"7","author":"Colpaert","year":"2006","journal-title":"Curr. Opin. Invest. Drugs"},{"issue":"6","key":"10.1016\/j.neuropharm.2020.107997_bib15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0028-3908(02)00119-3","article-title":"Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia","volume":"43","author":"Colpaert","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.107997_bib16","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/syn.20630","article-title":"The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats","volume":"63","author":"Eskow","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2020.107997_bib17","article-title":"Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers","author":"FDA","year":"2005"},{"key":"10.1016\/j.neuropharm.2020.107997_bib18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/BF00176841","article-title":"Rotational behavior induced by 8-hydroxy-DPAT, a putative 5HT-1A agonist, in 6-hydroxydopamine-lesioned rats","volume":"94","author":"Gerber","year":"1988","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2020.107997_bib19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys","volume":"15","author":"Gregoire","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2020.107997_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/nmt-2018-0017","article-title":"5-HT1A agonists and dyskinesia in Parkinson\u2019s disease: a pharmacological perspective","volume":"8","author":"Huot","year":"2018","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.neuropharm.2020.107997_bib21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.neuropharm.2015.05.033","article-title":"The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque","volume":"97","author":"Huot","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.107997_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuropharm.2015.01.012","article-title":"Activity of serotonin 5-HT receptor \u2018biased agonists\u2019 in rat models of Parkinson\u2019s disease and l-DOPA-induced dyskinesia","volume":"93C","author":"Iderberg","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.107997_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.expneurol.2015.05.021","article-title":"NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: behavioral and neurochemical profile in rat","volume":"271","author":"Iderberg","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2020.107997_bib25","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.107997_bib26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pbb.2004.07.015","article-title":"Effect of 5-HT1B\/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets","volume":"79","author":"Jackson","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2020.107997_bib27","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00702-011-0703-9","article-title":"Continuous drug delivery in early- and late-stage Parkinson\u2019s disease as a strategy for avoiding dyskinesia induction and expression","volume":"118","author":"Jenner","year":"2011","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2020.107997_bib28","article-title":"PET imaging of functional 5-HT1A receptors in hemiparkinsonian rats","volume":"2019","author":"Levigoureux","year":"2019","journal-title":"NeuroFrance"},{"key":"10.1016\/j.neuropharm.2020.107997_bib29","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1021\/acschemneuro.8b00584","article-title":"Serotonin 5-HT1A receptor biased agonists induce different cerebral metabolic responses: a [18F]FDG PET study in conscious and anesthetized rats","volume":"10","author":"Levigoureux","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.107997_bib30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bph.12894","article-title":"Side effect profile of 5-HT treatments for Parkinson\u2019s disease and L-DOPA-induced dyskinesia in rats","volume":"172","author":"Lindenbach","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.107997_bib31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00213-011-2569-9","article-title":"In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat","volume":"221","author":"Llado-Pelfort","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.107997_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.brainres.2006.07.003","article-title":"Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions","volume":"1112","author":"Matsubara","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.107997_bib34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.neuropharm.2016.01.013","article-title":"The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: a chronic administration study with microdialysis measurements","volume":"105","author":"McCreary","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.107997_bib35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.neuropharm.2016.01.013","article-title":"The novel 5-HT receptor agonist, NLX-112 reduces L-DOPA-induced abnormal involuntary movements in rat: a chronic administration study with microdialysis measurements","volume":"105","author":"McCreary","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.107997_bib36","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.expneurol.2017.03.013","article-title":"Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia","volume":"292","author":"Meadows","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2020.107997_bib37","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia","volume":"131","author":"Munoz","year":"2008","journal-title":"Brain\u202f: J. Neurol."},{"key":"10.1016\/j.neuropharm.2020.107997_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.neuropharm.2020.107997_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2018.03.016","article-title":"NLX-112, a highly selective 5-HT1A receptor agonist, mediates analgesia and antidepressant-like activity in rats via spinal cord and prefrontal cortex 5-HT1A receptors, respectively","volume":"1688","author":"Newman-Tancredi","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.107997_bib40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pbb.2017.11.002","article-title":"NLX-112, a highly selective 5-HT1A receptor agonist: effects on body temperature and plasma corticosterone levels in rats","volume":"165","author":"Newman-Tancredi","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2020.107997_bib41","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/jphp.12762","article-title":"Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist","volume":"69","author":"Newman-Tancredi","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.107997_bib42","series-title":"Pierre Fabre Medicament","article-title":"A method for treating movement disorders with befiradol","author":"Paillard","year":"2016"},{"issue":"6","key":"10.1016\/j.neuropharm.2020.107997_bib60","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov Disord"},{"key":"10.1016\/j.neuropharm.2020.107997_bib43","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0006-3223(85)90194-5","article-title":"Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors","volume":"20","author":"Peroutka","year":"1985","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.107997_bib44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/14740338.2015.988137","article-title":"Therapeutic strategies to prevent and manage dyskinesias in Parkinson\u2019s disease","volume":"14","author":"Pilleri","year":"2015","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.neuropharm.2020.107997_bib45","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson\u2019s disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2020.107997_bib46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00008877-200006000-00013","article-title":"Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy","volume":"11","author":"Prinssen","year":"2000","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.107997_bib47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/026988110201600301","article-title":"Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride","volume":"16","author":"Rabiner","year":"2002","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.107997_bib48","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.clineuro.2013.08.022","article-title":"Pain in Parkinson\u2019s disease: analysis and literature review","volume":"115","author":"Rana","year":"2013","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.107997_bib49","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/00207454.2014.994208","article-title":"Association of restless legs syndrome, pain, and mood disorders in Parkinson\u2019s disease","volume":"126","author":"Rana","year":"2016","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.107997_bib51","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1212\/WNL.0000000000002494","article-title":"Serotonin-to-dopamine transporter ratios in Parkinson disease: relevance for dyskinesias","volume":"86","author":"Roussakis","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.107997_bib52","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrd2087","article-title":"Novel pharmacological targets for the treatment of Parkinson\u2019s disease","volume":"5","author":"Schapira","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2020.107997_bib53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40478-018-0653-7","article-title":"Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia","volume":"7","author":"Sellnow","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neuropharm.2020.107997_bib54","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/0091-3057(86)90477-6","article-title":"Differential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndrome","volume":"24","author":"Smith","year":"1986","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2020.107997_bib55","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nbd.2013.08.014","article-title":"5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson\u2019s disease model","volume":"60","author":"Tronci","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2020.107997_bib56","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1124\/jpet.117.247171","article-title":"Predictive value of parkinsonian primates in pharmacologic studies: a comparison between the macaque, marmoset, and squirrel monkey","volume":"365","author":"Veyres","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.107997_bib57","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s00429-018-1672-7","article-title":"(18)F-F13640 preclinical evaluation in rodent, cat and primate as a 5-HT1A receptor agonist for PET neuroimaging","volume":"223","author":"Vidal","year":"2018","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.neuropharm.2020.107997_bib58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuropharm.2016.05.009","article-title":"Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer\u2019s disease: a post-mortem study with PET radiopharmaceuticals","volume":"109","author":"Vidal","year":"2016","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.neuropharm.2020.107997_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyw079","article-title":"Marmoset serotonin 5-HT1A receptor mapping with a biased agonist PET probe 18F-F13714: comparison with an antagonist tracer 18F-MPPF in Awake and anesthetized states","volume":"19","author":"Yokoyama","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820300630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820300630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:00:17Z","timestamp":1758438017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820300630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":57,"alternative-id":["S0028390820300630"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.107997","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.107997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107997"}}